

## RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING

Milan, 27<sup>th</sup> March 2023 – Pursuant to art. 144-octies, paragraph 2 of Consob's Regulation 11971/1999 as amended from time to time (the "Issuers' Regulations") RECORDATI S.p.A. informs that, as of today, the only slate which has been filed with reference to the appointment of the Board of Statutory Auditors for the period 2023-2025 in the agenda of the Shareholders' General Meeting of 21<sup>st</sup> April 2023, single call, is the one presented by the majority shareholder Rossini S.à r.l..

Therefore, pursuant to art. 144-sexies, paragraph 5, of the aforementioned Issuers Regulations and also pursuant to the Company's By-laws, the deadline for filing further slates for the appointment of the Company's Board of Statutory Auditors is extended to 30<sup>th</sup> March 2023 (at 6:00 pm for hand delivery), and the minimum threshold for the submission of slates, fixed at 1% of the Company's share capital having voting rights, is reduced by half, i.e. to 0,5% of the share capital having voting rights.

For the purpose of filing any additional slates, please refer to the notice of call of the aforementioned Shareholders' General Meeting and to the specific explanatory report of the Board of Directors, already published in accordance with the law and available to the public at the Company's registered office, on the Company's website ([www.recordati.it](http://www.recordati.it), under the section "Investors/Shareholders' Meetings"), as well as on the authorised storage mechanism 1INFO ([www.1info.it](http://www.1info.it)).

Finally, it should be noted that the majority slate for the renewal of the Board of Statutory Auditors submitted by Rossini S. à r.l. and any additional slates filed pursuant to art. 144-sexies, paragraph 5, of the Issuers' Regulations will be made available to the public by Friday 31<sup>st</sup> March 2023 in the manner set by current legislation.

*Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a global specialised business, dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was € 1,853.3 million, operating income was € 437.3 million and net income was € 312.3 million.*

For further information:

Recordati website: [www.recordati.it](http://www.recordati.it)

[Investor Relations](#)

[Investor Relations](#)

[Media Relations](#)

### RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1  
20148 Milano, Italy  
Ph. (39) 02 487871  
Fax (39) 02 40073747  
[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l



Federica De Medici  
(39) 02 48787146

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Lucia Abbatantuoni  
(39) 02 48787213

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Brunswick: Barbara Scalchi / Andrea Mormandi  
(39) 02 9288 6200

e-mail: [recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)